The Global Erectile Dysfunction Devices Market Report is a comprehensive research report that focuses on the consumption structure, developments, trends, sales models, and sales of top countries in the market.
The market report provides an in-depth analysis of the industry’s vertical, emphasizing on the market share, size and trends, growth drivers, key players, opportunities, and limitations in the forthcoming years.
According to experts, the Global Erectile Dysfunction Devices market is expected to grow considerably, recording a good CAGR between 2020 and 2025.
Typically, erectile dysfunction (ED) is treated with oral medications such as Viagra (sildenafil), Cialis, (tadalafil), Levitra (vardenafil), or Stendra (avanafil). However, some men face issues like drug side effects and in those patients, devices such as vacuum constriction devices (VCDs) or penile pumps are advised.
Fluctuations in the demand and supply of ED devices due to the strict lockdown measures to address the ongoing coronavirus pandemic have left several organizations in disarray.
Due to the current global situation and the uncertainty of revenue, the industry is expected to face some challenges even if the economy reopens after the pandemic.
Considering the current health crisis, the report offers a comprehensive and detailed assessment of the industry segments to help users understand the revenue prospects of the industry.
The report covers key insights on the growth matrix amid COVID-19 pandemic, key market players operating in the industry, statistical analysis, CAGR of the market, etc.
The Global ED Devices Market report also mentions the advantages and disadvantages of the direct and indirect sale channels, growth prospects until 2025, and regional analysis according to North America, Latin American, Europe, Asia-Pacific, and the Middle East and Africa
The global ED devices spectrum also includes inflatable penile implant and semi-rigid rod implant. The application arena includes congenital patients and pathological patients.
Key players include Eli Lilly, Dong-A Socio, Boston Scientific, Pfizer, Bayer, Futura Medical, Teva Pharmaceuticals, among others. The report is available at aeresearch.net.
